Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT ID: NCT01453504
Last Updated: 2019-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
73 participants
INTERVENTIONAL
2012-08-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to determine the recommended dose of everolimus for a subsequent Phase II trial
2. to determine the efficacy of everolimus plus DHAP
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
NCT01022996
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT01075321
Study of Everolimus (RAD001) in Combination With Lenalidomide
NCT01218555
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00671112
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
NCT01059318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ever-DHAP
Combination of Everolimus and DHAP
DHAP
Dexamethasone, Cytarabine, Cisplatin
Everolimus
Placebo-DHAP
DHAP
Dexamethasone, Cytarabine, Cisplatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DHAP
Dexamethasone, Cytarabine, Cisplatin
Everolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-60
* histology confirmed relapse
Exclusion Criteria
* current CNS involvement
* other primary malignant disease within the last 3 years
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Peter Borchmann
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Borchmann, Prof.
Role: STUDY_CHAIR
University of Cologne, German Hodgkin Study Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1st Dept. of Medicine, Cologne University Hospital
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Homepage GHSG
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD-R3i
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.